Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

FMBFarma granted exclusive rights to market Ampio's Zertane for PE in Brazil

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, and FBM Industria Farmaceutica Ltda, a member of the HOSPFAR Group that manufactures, imports and distributes pharmaceuticals in Brazil, today announced a license and distribution agreement providing FMBFarma exclusive rights to market Zertane in Brazil for the treatment of premature ejaculation.

22 Mar 2012

First Edition: March 22, 2012

Today's headlines include examinations of the health law as it approaches its two-year anniversary and its review by the Supreme Court, as well as reports about what's next for the Ryan budget plan.

22 Mar 2012

IQMS releases new version of ERP software, EnterpriseIQ

IQMS, a manufacturing ERP software developer with an ongoing, proactive commitment to its product and relationships, today announced the release of a new version of its manufacturing ERP software, EnterpriseIQ. Featuring more than 1,000 enhancements and reports across all aspects of the system, IQMS' newest release again demonstrates its commitment to the product and its clients.

21 Mar 2012

ISCO fourth quarter revenue increases 110% to $1.1 million

International Stem Cell Corporation today announced year-end financial results for the year ended December 31, 2011.

21 Mar 2012

IGI fourth quarter total revenues increase 21% to $2.1M

IGI Laboratories, Inc., a New Jersey based topical generic drug development and manufacturing company, provided its financial results for the fourth quarter and year ended December 31, 2011.

21 Mar 2012

Ampio receives U.S. patent allowance for lead drug Ampion

Ampio Pharmaceuticals, Inc., a biopharmaceutical company conducting clinical trials on its three lead drugs, licensing distribution of these drugs and engaged in further drug development, today announced that it has received notice of allowance from the US Patent Office of an additional patent that complements and expands its anti inflammatory patent portfolio for its lead drug Ampion.

20 Mar 2012

Tobii completes USD $21 million funding round

Tobii Technology, the global leader in eye tracking and gaze interaction, announced today that it has closed a USD $21M funding round. New investor Intel Capital joins existing investors Amadeus Capital, Investor Growth Capital and Northzone Ventures.

20 Mar 2012

QRxPharma, Actavis enter License and Option Agreement

QRxPharma Limited announced today execution of its License and Option Agreement with Actavis, Inc. which finalised the legal terms and conditions to commercialise MoxDuo IR in the US acute pain marketplace. The LOA completion follows a 20 December 2011 signing of a binding Letter of Intent secured by a US$6 million non-refundable upfront signing fee to QRxPharma.

19 Mar 2012

PaxVax announces FDA acceptance of IND for PXVX-0200 cholera vaccine

PaxVax Corporation, developer of innovative and socially responsible oral vaccines against infectious diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for its single-dose oral cholera vaccine, clearing the way to begin clinical trials. The company intends to begin Phase 3 trials later this year.

19 Mar 2012

Repligen total revenue increases to $7,165,000 for quarter ended December 31, 2011

Repligen Corporation today reported financial results for the quarter and nine-month fiscal year ended December 31, 2011.

17 Mar 2012

OHRI, uOttawa to lead first stem cell therapy trial for septic shock

A team of researchers from the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa (uOttawa) has been awarded $367,000 from the Canadian Institutes of Health Research (CIHR) and $75,000 from the Stem Cell Network to lead the first clinical trial in the world of a stem cell therapy for septic shock.

16 Mar 2012

New evidence on the link between suicide and economy

New evidence on the link between suicide and the economy shows that the monthly suicide rate in New York City from 1990 to 2006 was 29% higher at the economic low point in 1992 than at the peak of economic growth in 2000.

16 Mar 2012

SIPP secures necessary financing commitment from First Fidelity

SIPP International Industries, Inc., the diversified parent company to several divisions in the food, medical, hotel and broadcasting industries, has secured its necessary financing commitment from First Fidelity, Inc. for the manufacturing of the SIPP product lines.

16 Mar 2012

Food borne ailments from imported products on the rise: CDC report

Food-borne illnesses caused by fish, spices, produce and other edibles imported from other countries seems to be on the rise – but the countries of origin may be varied, according to a new report from the Centers for Disease Control and Prevention. The CDC defines a food borne disease outbreak as two or more similar illnesses resulting from the same type of food.

15 Mar 2012

GenMark Diagnostics fourth quarter revenues increase to $2.0 million

GenMark Diagnostics, Inc. today reported additional financial information for the fourth quarter ended December 31, 2011 that was unavailable at the time it released preliminary financial results on March 8, 2012.

15 Mar 2012

GenVec 2011 net loss decreases to $7.4 million

Today GenVec, Inc. announced financial results for the fourth quarter and year ended December 31, 2011. For the year ended December 31, 2011, the Company reported a net loss of $7.4 million, or $0.58 per share, compared with a net loss of $12.3 million, or $0.97 per share, for the year ended December 31, 2010.

15 Mar 2012

Insmed fourth quarter revenues increase to $1.4 million

Insmed Incorporated, a biopharmaceutical company, today reported results for the fourth quarter and fiscal year ended December 31, 2011.

13 Mar 2012

Bend Research announces licensing agreement with Affinium

Bend Research Inc., a leading independent drug-formulation development and manufacturing company, today announced a licensing agreement with Affinium Pharmaceuticals, Ltd.

13 Mar 2012

Agennix, DSM sign new contract to manufacture talactoferrin for NSCLC

DSM Pharmaceutical Products, the custom manufacturing business of Royal DSM N.V., and Agennix AG have signed a new contract under which DSM will continue to manufacture talactoferrin for Agennix at commercial levels.

13 Mar 2012

BDSI announces postponement of ONSOLIS U.S. relaunch

BioDelivery Sciences International, Inc. today announced that the U.S. relaunch of ONSOLIS (fentanyl buccal soluble film) is being postponed until the product formulation can be modified to address two appearance issues raised by the U.S. Food and Drug Administration (FDA) following a recent inspection of the Aveva manufacturing facility where ONSOLIS is produced.

12 Mar 2012